# OnCo record idea-tnbc-adc-sequencing-trial (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-tnbc-adc-sequencing-trial/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-tnbc-adc-sequencing-trial" ;
  schema:name "A randomised trial of antibody-drug conjugate sequence in metastatic triple-negative breast cancer"@en ;
  schema:description "Three antibody-drug conjugates now used in triple-negative breast cancer carry the same kind of chemotherapy warhead, a topoisomerase inhibitor. Nobody has randomised which to give first or whether the second works after the first; small series suggest it often does not. With two now approved first line, the question decides what a patient gets for the rest of her life."@en ;
  schema:url <https://onco.cc/ideas/idea-tnbc-adc-sequencing-trial/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://europepmc.org/article/MED/41937088>, <https://europepmc.org/article/MED/33882206> ;
  onco:tag "tnbc-evidence" ;
  onco:related <https://onco.cc/roadmaps/trop2-adc-roadmap/>, <https://onco.cc/roadmaps/adc-generations/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/her2-low-metastatic-breast-cancer/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/>, <https://onco.cc/technologies/trop2-pet/> ;
  onco:targets <https://onco.cc/targets/trop2/>, <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/> ;
  onco:companies <https://onco.cc/companies/gilead/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/daiichi-sankyo/> ;
  onco:terms <https://onco.cc/terms/adc-sequencing/>, <https://onco.cc/pairings/adc-after-adc-caution/>, <https://onco.cc/terms/her2-low/>, <https://onco.cc/terms/pfs/> ;
  onco:trials <https://onco.cc/trials/ascent/>, <https://onco.cc/trials/ascent-03/>, <https://onco.cc/trials/tropion-breast02/>, <https://onco.cc/trials/destiny-breast04/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-resistance/>, <https://onco.cc/bottlenecks/b-combination-space/>, <https://onco.cc/bottlenecks/b-trial-design/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-ascent-nejm-2021/>, <https://onco.cc/key-papers/paper-tropion-breast02-ann-oncol-2026/>, <https://onco.cc/key-papers/paper-destiny-breast04-nejm-2022/>, <https://onco.cc/key-papers/paper-asco-biomarkers-metastatic-breast-cancer-guideline-jco-2022/> .
